Seer
JPM Healthcare Conference Day 1: Seer, Twist, 10x, Guardant, Natera, Bruker, Adaptive, Qiagen, Sema4
Highlights of the first day included updates on Seer's new proteomics platform and a new enzymatic DNA synthesis chemistry from Twist Bioscience.
Seer Collaborators Release Data Indicating Proteograph Platform's Utility for Proteomics Research
Premium
The company and its early-access users have recently published data from several studies indicating that its platform can boost plasma proteome coverage.
Seer Q3 Revenues Spike but Firm Misses Wall Street Estimate on Earnings
The proteomics firm posted revenues of $2.2 million, up from $72,000 in the year-ago period and above the consensus Wall Street estimate of $1.2 million.
Seer Q2 Revenues Skyrocket; Firm Inks Chinese Distribution Deal
The company posted revenues of $1.3 million, up from $71,000 in the year-ago period and above the consensus Wall Street estimate of $790,000.
Seer Q1 Revenues Fall on Decline in Grant Revenue
The Redwood City, California-based proteomics firm posted revenues of $62,000, down from $177,000 in the year-ago period due a decline in grant revenue.
Jan 28, 2021
Seer Prices $110.5M Follow-on Stock Offering
Jan 26, 2021